Shares of Akeso Tumble After U.S. Drug Regulator Rejected Cancer Medicine It Developed
By Tracy QuShares of Akeso slumped in Hong Kong after the U.S. drug regulator rejected a cancer medicine developed by the firm.The stock fell as much as 32% on Monday, before paring some losses to be 22% lower at 63.95 Hong Kong dollars, equivalent to US$8.15. In comparison the headline Hang Seng I…